Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Detalles Bibliográficos
Autores principales: Frigault, Matthew J., Nikiforow, Sarah, Mansour, Michael K., Hu, Zhen-Huan, Horowitz, Mary M., Riches, Marcie L., Hematti, Peiman, Turtle, Cameron J., Zhang, Mei-Jie, Perales, Miguel-Angel, Pasquini, Marcelo C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. 2020
Materias:
Letters to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332891/
https://www.ncbi.nlm.nih.gov/pubmed/32457999
http://dx.doi.org/10.1182/blood.2020006216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332891/
https://www.ncbi.nlm.nih.gov/pubmed/32457999
http://dx.doi.org/10.1182/blood.2020006216

Ejemplares similares